NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free RKDA Stock Alerts $3.07 +0.14 (+4.78%) (As of 12:39 PM ET) Add Compare Share Share Today's Range$2.91▼$3.0750-Day Range$1.89▼$3.2752-Week Range$1.85▼$5.60Volume8,180 shsAverage Volume26,506 shsMarket Capitalization$4.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Arcadia Biosciences alerts: Email Address Arcadia Biosciences MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside95.4% Upside$6.00 Price TargetShort InterestHealthy0.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.29) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 stars 3.8 Analyst's Opinion Consensus RatingArcadia Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Arcadia Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.88% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 50.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RKDA. Previous Next 3.7 News and Social Media Coverage News SentimentArcadia Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Basic Materials companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.Search Interest9 people have searched for RKDA on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows5 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 17.73% of the stock of Arcadia Biosciences is held by institutions.Read more about Arcadia Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Arcadia Biosciences are expected to grow in the coming year, from ($2.29) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Arcadia Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About Arcadia Biosciences Stock (NASDAQ:RKDA)Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.Read More RKDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RKDA Stock News HeadlinesMay 27 at 1:26 AM | americanbankingnews.comEquities Analysts Set Expectations for Arcadia Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:RKDA)May 25 at 2:56 AM | americanbankingnews.comHC Wainwright Weighs in on Arcadia Biosciences, Inc.'s Q1 2025 Earnings (NASDAQ:RKDA)May 24, 2024 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Given New $6.00 Price Target at HC WainwrightMay 23, 2024 | markets.businessinsider.comOptimizing Growth: Arcadia Biosciences’ Strategic Divestitures and Expanding Market ShareMay 23, 2024 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.comMay 17, 2024 | businesswire.comArcadia Biosciences (RKDA) To Host Investor Call To Discuss Recent TransactionsMay 16, 2024 | markets.businessinsider.comArcadia Biosciences Agrees To Sell GoodWheat Brand Products Above Food For $4 MlnMay 16, 2024 | businesswire.comArcadia Biosciences (RKDA) Announces Sale of GoodWheatTM to Above Food Corp.May 14, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on Arcadia Biosciences (RKDA)May 14, 2024 | businesswire.comArcadia Biosciences (RKDA) Announces Sale of Resistant Starch Durum Wheat Trait to Corteva Agriscience (CTVA)May 11, 2024 | finance.yahoo.comArcadia Biosciences First Quarter 2024 Earnings: Beats ExpectationsMay 11, 2024 | finance.yahoo.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV), Aziyo Biologics (ELUT) and Arcadia Biosciences (RKDA)May 9, 2024 | investorplace.comRKDA Stock Earnings: Arcadia Biosciences Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | businesswire.comArcadia Biosciences (RKDA) Announces First Quarter 2024 Financial Results and Business HighlightsApril 25, 2024 | businesswire.comArcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference CallApril 17, 2024 | msn.comSNDL, Arcadia Biosciences among Consumer Staples moversApril 6, 2024 | markets.businessinsider.comBuy Rating on Arcadia Biosciences Fueled by Strategic Initiatives and Innovative Product LaunchesApril 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcadia Biosciences Amidst Growth and Strategic ShiftsApril 1, 2024 | sg.news.yahoo.comMicrosoft unbundles Teams and Office 365 for customers worldwideApril 1, 2024 | finance.yahoo.comArcadia Biosciences Full Year 2023 Earnings: Misses ExpectationsApril 1, 2024 | finance.yahoo.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | seekingalpha.comArcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Arcadia Biosciences Inc Earnings CallMarch 28, 2024 | sfgate.comArcadia Biosciences: Q4 Earnings SnapshotSee More Headlines Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/28/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBasic Materials Industry Agricultural production - crops Sub-IndustryN/A Current SymbolNASDAQ:RKDA CUSIPN/A CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees21Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+95.4%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-129.74% Pretax Margin-117.85% Return on Equity-84.27% Return on Assets-55.17% Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio3.41 Sales & Book Value Annual Sales$5.33 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$11.44 per share Price / Book0.27Miscellaneous Outstanding Shares1,360,000Free Float1,338,000Market Cap$4.18 million OptionableNot Optionable Beta0.62 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stanley E. Jacot Jr. (Age 53)President, CEO & Director Comp: $527.9kMr. Thomas J. Schaefer (Age 48)CFO & Corporate Secretary Mr. Tracy BakerSenior Vice President of Seamless Technical OperationsKey CompetitorsIT Tech PackagingNYSE:ITPGolden MineralsNYSE:AUMNChina Natural ResourcesNASDAQ:CHNRAustin GoldNYSE:AUSTForemost Lithium Resource & TechnologyNASDAQ:FMSTView All CompetitorsInsidersThomas J SchaeferBought 700 shares on 2/1/2024Total: $1,442.00 ($2.06/share)Thomas J SchaeferBought 649 shares on 8/4/2023Total: $2,381.83 ($3.67/share)Stanley Jacot JrBought 5,000 shares on 5/30/2023Total: $21,550.00 ($4.31/share)View All Insider Transactions RKDA Stock Analysis - Frequently Asked Questions Should I buy or sell Arcadia Biosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" RKDA shares. View RKDA analyst ratings or view top-rated stocks. What is Arcadia Biosciences' stock price target for 2024? 2 brokerages have issued 12 month price targets for Arcadia Biosciences' shares. Their RKDA share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 95.4% from the stock's current price. View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts. How have RKDA shares performed in 2024? Arcadia Biosciences' stock was trading at $3.13 at the beginning of the year. Since then, RKDA shares have decreased by 1.9% and is now trading at $3.07. View the best growth stocks for 2024 here. Are investors shorting Arcadia Biosciences? Arcadia Biosciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 5,300 shares, a decline of 50.5% from the April 30th total of 10,700 shares. Based on an average daily trading volume, of 30,000 shares, the short-interest ratio is presently 0.2 days. Currently, 0.9% of the shares of the stock are short sold. View Arcadia Biosciences' Short Interest. When is Arcadia Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our RKDA earnings forecast. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its quarterly earnings results on Thursday, May, 9th. The basic materials company reported ($1.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.52) by $0.74. The basic materials company had revenue of $1.26 million for the quarter, compared to analysts' expectations of $1.20 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 84.27% and a negative net margin of 129.74%. During the same quarter in the previous year, the company posted ($3.83) earnings per share. When did Arcadia Biosciences' stock split? Arcadia Biosciences shares reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO? 1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RKDA) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe only AI company to buyPorter & CompanyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
